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Summary  Effective  regenerative  treatments  for  periodontal  tissue  defects  have  recently  been
demonstrated  using  mesenchymal  stromal/stem  cells  (MSCs).  Furthermore,  current  bioengi-
neering techniques  have  enabled  de  novo  fabrication  of  tooth-perio  dental  units  in  mice.  These
cutting-edge  technologies  are  expected  to  address  unmet  needs  within  regenerative  dentistry.
However,  to  achieve  efﬁcient  and  stable  treatment  outcomes,  preparation  of  an  appropriate
stem cell  source  is  essential.  Many  researchers  are  investigating  the  use  of  adult  stem  cells  forPlease  cite  this  article  in  press  as:  Niibe  K,  et  al.  The  potential  of  enriched  mesenchymal  stem  cells  with  neu-
ral  crest  cell  phenotypes  as  a  cell  source  for  regenerative  dentistry.  Japanese  Dental  Science  Review  (2016),
http://dx.doi.org/10.1016/j.jdsr.2016.09.001
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regenerative  dentistry;  bone  marrow-derived  MSCs  (BM-MSCs)  are  particularly  promising  and
presently used  clinically.  However,  current  BM-MSC  isolation  techniques  result  in  a  heteroge-
neous, non-reproducible  cell  population  because  of  a  lack  of  identiﬁed  distinct  BM-MSC  surface
markers. Recently,  speciﬁc  subsets  of  cell  surface  markers  for  BM-MSCs  have  been  reported
in mice  (PDGFR+ and  Sca-1+)  and  humans  (LNGFR+,  THY-1+ and  VCAM-1+),  facilitating  the
isolation of  unique  enriched  BM-MSCs  (so-called  ‘‘puriﬁed  MSCs’’).  Notably,  the  enriched  BM-MSC
∗ Corresponding author at: Division of Molecular and Regenerative Prosthodontics, Tohoku University Graduate School of Dentistry, 4-1
Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. Fax: +81 22 717 8367.
E-mail address: egu@dent.tohoku.ac.jp (H. Egusa).
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population  contains  neural  crest-d
and mesenchymal  lineages.  In  thi
with a  focus  on  their  potential  ap
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. Introduction
ollowing  tooth  loss,  damage  to  periodontal  tissues  or
aw  bones  caused  by  dental  caries,  periodontal  disease,
r  tumor  extraction,  it  is  difﬁcult  for  humans  to  self-
egenerate  the  lost  tissues  [1].  Current  dental  therapies
herefore  use  artiﬁcial  materials  and  prostheses  to  restore
ost  dental  structures.  However,  limitations  of  these  thera-
ies  include  incomplete  recovery  of  functional  tissues  and
sthetic  issues  [2].  Therefore,  regenerative  therapies  are
eceiving  increased  attention  within  the  dental  ﬁeld  [3].
or  example,  patients  with  reduced  alveolar  bone  height
ften  undergo  alveolar  bone  augmentation  before  a  den-
al  implant  can  be  placed.  Presently,  autograft,  allograft,
enograft,  and  bone  grafting  materials  are  used  for  alveolar
one  augmentation;  however,  it  is  difﬁcult  to  maintain  the
rafted  bone  height  and  volume  for  a  long  period  after  the
ugmentation  treatment  [4],  even  following  autograft  bone
ugmentation  [5,6],  which  is  considered  the  gold-standard
rocedure.
Several  studies  have  shown  that  fetal  dental  epithelium
nd  dental  mesenchyme  can  be  suitable  cell  sources  for  bio-
ngineered  teeth  [7,8]  that  erupt  at  the  transplant  site  of
ouse  alveolar  bone  defects  [9].  A  more  recent  technologi-
al  approach  for  bioengineered  teeth  involves  fabricating  a
ooth  structure  using  periodontal  tissues,  including  alveolar
one  [10].  Therefore,  stem  cell-based  therapy  is  expected
o  be  a  powerful  tool  in  regenerative  dentistry,  with  many
esearchers  engaging  in  stem  cell  biology  and  tissue  engi-
eering  research  to  establish  cell-based  approaches  to
egenerative  dentistry  [11].
proliferative  cells  that  are  able  to  differentiate  into
osteoblasts,  adipocytes  and  chondrocytes  [17]. Human  BM-
MSCs  (hBM-MSCs)  are  now  clinically  applied  world-wide
because  of  their  proliferative  ability  and  multi-potent  dif-
ferentiation  potential.
One  potential  problem  of  using  hBM-MSCs  is  that  their
therapeutic  success  rate  varies  among  patients,  partly
because  BM-MSCs  as  a  population  are  heterogeneous  and
contain  progenitors  of  osteoblasts,  adipocytes,  chondro-
cytes,  and  other  mononuclear  cells  [18,19].  According  to
the  2006  statement  of  the  International  Society  for  Cel-
lular  Therapy  [20],  hBM-MSCs  are  minimally  deﬁned  by
their  (1)  capacity  to  attach  to  tissue  culture-treated  plas-
tic  dishes,  (2)  speciﬁc  surface  antigen  expression  [CD105+,
CD73+,  CD90  (known  as  THY-1)+,  CD45−,  CD34−,  CD14− or
CD11b−, CD79a− or  CD19−,  and  HLA-DR−],  and  (3)  mul-
tipotent  differentiation  potential.  However,  these  criteria
are  not  deﬁnitive,  and  the  statement  mentioned  that  the
criteria  would  require  modiﬁcation  as  new  facts  and  data
become  available  [20].  A  lack  of  speciﬁc  cell  surface  markers
to  deﬁne  BM-MSCs  has  hampered  progress  in  understanding
the  molecular  basis  of  their  clonal  potential.  In  contrast,
speciﬁc  markers  for  HSCs  and  HSC-derived  hematopoietic
lineage  cells  are  well-established  [21,22]; therefore  these
cells  can  be  successfully  isolated  and  analyzed  using  ﬂow
cytometry  [12,23].  Based  on  the  resulting  understanding  of
HSC  characteristics,  remarkable  and  reproducible  progress
in  transplant  therapy  using  HSCs  has  been  achieved  [24].
To  provide  standardized  BM-MSC-based  treatment  out-
comes,  it  is  therefore  important  to  pursue  and  deﬁne
speciﬁc  BM-MSC  markers.  Recently,  combinations  of  cellPlease  cite  this  article  in  press  as:  Niibe  K,  et  al.  The  po
ral  crest  cell  phenotypes  as  a  cell  source  for  regenerati
http://dx.doi.org/10.1016/j.jdsr.2016.09.001
There  are  basically  two  types  of  stem  cells  in  bone
arrow:  hematopoietic  stem  cells  (HSCs)  [12—15]  and
esenchymal  stromal/stem  cells  (MSCs)  [16,17]. Bone
arrow-derived  MSCs  (BM-MSCs)  are  plastic-adherent  and
s
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erived  cells,  which  can  differentiate  into  cells  of  neural  crest-
s  review,  characteristics  of  the  enriched  BM-MSCs  are  outlined
plication  within  future  regenerative  dentistry.
 by  Elsevier  Ltd  on  behalf  of  Japanese  Association  for  Dental
ticle  under  the  CC  BY-NC-ND  license  (http://creativecommons.
urface  markers  for  BM-MSCs,  including  PDGFR+ and  Sca-tential  of  enriched  mesenchymal  stem  cells  with  neu-
ve  dentistry.  Japanese  Dental  Science  Review  (2016),
+ (PS)  in  mice  [25]  and  LNGFR+, THY-1+,  and  VCAM-1+
LTV)  in  humans  [26],  have  been  identiﬁed.  These  marker
ombinations  enable  the  prospective  isolation  of  highly
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Figure  1  Schematic  diagram  illustrating  neural  crest  cell  (NCC)  location  and  progression.  In  the  early  embryo,  the  neural  tube
is formed  and  epithelial  cells  at  the  dorsal  region  of  the  neural  tube  undergo  an  epithelial-to-mesenchymal  transition  to  become
migratory NCCs.  NCCs  migrating  from  cranial  and  trunk  regions  of  the  neural  tube  differentiate  into  many  diverse  derivatives  of
mesenchymal-  and  ectodermal-lineage  cells  and  tissues.  In  craniofacial  development,  cranial  NCCs  contribute  to  ectodermal  tissues
and mesenchymal  tissues,  including  dental  mesenchyme  components,  such  as  the  dentin,  dental  pulp,  periodontal  ligament,  gingival
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sconnective tissue,  cementum,  and  alveolar  bone.  Trunk  NCCs  
nervous system.  A  small  mesenchymal  contribution  by  trunk  NC
enriched  BM-MSC  populations  [25,26],  so-called  ‘‘puriﬁed
MSCs’’,  which  show  unique  characteristics.  Interestingly,
recent  studies  have  shown  that  the  enriched  BM-MSCs
exhibit  phenotypes  of  neural  crest  cells  (NCCs)  [25,27],
which  are  a  multipotent  migratory  stem  cell  population.
Indeed,  a  sub-population  of  BM-MSCs  originates  from  NCCs
[28].  Notably,  during  embryonic  development,  most  cra-
nial  NCCs  differentiate  into  cells  of  mesenchymal  lineage,
including  osteoblasts,  adipocytes,  chondrocytes  [29], and
dental  mesenchyme  [30].
In  this  review,  a  speciﬁc  combination  of  markers  for
identifying  and  isolating  enriched  BM-MSCs  and  their  unique
characteristics  are  introduced.  The  future  prospects  of  using
these  enriched  BM-MSCs  for  regenerative  dentistry  are  also
discussed.
2. Neural crest cells (NCCs)
NCCs,  known  as  the  fourth  germ  layer,  spread  throughout
the  body  following  migration  from  the  neural  tube  dur-
ing  fetal  development  [28,29,31].  In  1992,  Anderson  et  al.
[32]  succeeded  in  isolating  multi-potent  and  self-renewing
NCCs  (neural  crest  stem  cells:  NCSCs).  Within  the  embryo,
NCCs  are  detected  at  the  border  of  the  neural  plate  and
the  non-neural  ectoderm  after  gastrulation.  The  borders
of  the  neural  plate  (neural  folds)  converge  at  the  dor-
sal  midline  to  form  the  neural  tube  during  neurulation.
Subsequently,  NCCs  that  have  migrated  from  the  neural
tube  undergo  an  epithelial-to-mesenchymal  transition  (EMT)
[29].  After  the  EMT,  NCCs  leave  the  dorsal  neural  tube  and
migrate  into  other  embryonic  tissues  in  the  head  and  trunkPlease  cite  this  article  in  press  as:  Niibe  K,  et  al.  The  po
ral  crest  cell  phenotypes  as  a  cell  source  for  regenerati
http://dx.doi.org/10.1016/j.jdsr.2016.09.001
regions  (Fig.  1).  As  a  result,  there  are  mainly  two  types  of
NCCs  in  the  body,  i.e., trunk  and  cranial  NCCs  [33],  both
of  which  can  be  identiﬁed  by  their  Hox  gene  expression
pattern  [33,34].
c
m
crentiate  mainly  into  neurons  and  glial  cells  of  the  peripheral
s  also  been  reported.
.1.  Trunk  NCCs
ost  trunk  NCCs  differentiate  into  cells  of  ectodermal  lin-
age,  such  as  neurons,  glia,  and  melanocytes  [35,36].  A
ery  small  mesenchymal  contribution  by  trunk  NCCs  has
een  observed  in  endoneurial  ﬁbroblasts  of  the  sciatic  nerve
36,37].  In  addition,  previous  studies  indicated  that  a  cer-
ain  population  of  mBM-MSCs  from  leg  bones  (the  femur  and
ibia)  originates  from  trunk  NCCs  [25,28,31].  It  is  now  clear
hat  trunk  NCCs  in  amniotes  have  the  capacity  to  give  rise  to
iverse  mesenchymal  phenotypes,  including  skeletal  cells,
nder  speciﬁc  conditions  in  vitro  and  in  vivo. In  appropriate
ulture  conditions,  trunk  NCSCs  differentiate  into  cells  of
esenchymal  lineage,  such  as  osteoblasts  [25],  adipocytes
38,39],  chondrocytes  [40,41], and  myoﬁbroblasts  [38].
.2.  Cranial  NCCs
ranial  NCCs  differentiate  into  a  wider  range  of  cell
ypes  than  trunk  NCCs  during  normal  development  [38].
uring  embryonic  development,  most  cranial  NCCs  differen-
iate  into  mesenchymal  lineage  cells,  including  osteoblasts,
dipocytes,  chondrocytes  [29], and  dental  mesenchyme
30]. After  migration  in  the  head  regions  of  the  embryo,
ranial  NCCs  invade  the  surrounding  cranial  mesenchyme
nd  ultimately  cease  migration,  coalesce,  and  form  the
arious  cranial  ganglia,  craniofacial  cartilage  and  bones
42,43],  and  dental  mesenchyme,  such  as  dentin,  den-
al  pulp,  cementum,  and  periodontal  ligament  [30,44—48]
Fig.  1).  In  addition,  some  NCCs  are  preserved  as  NCSCs  in
dult  craniofacial  tissues,  such  as  the  nasal  turbinates  [49],
ubmandibular  glands  [50],  palate,  gingiva,  tongue,  and  buc-tential  of  enriched  mesenchymal  stem  cells  with  neu-
ve  dentistry.  Japanese  Dental  Science  Review  (2016),
al  mucosa  [51,52].
Collectively,  these  data  demonstrate  that  NCCs  have
ulti-differentiation  potential.  In  particular,  NCCs  in  the
raniofacial  tissues  possess  the  potential  to  undergo
ARTICLE IN PRESS+ModelJDSR-169; No. of Pages 9
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Table  1  Previously  reported  surface  markers  of  human  and  mouse  multipotent  mesenchymal  stromal/stem  cells.
Cell  surface  marker Human  Mouse  Distribution
CD11b/Integrin  M  −  −  Myeloid,  macrophage,  NK  cells,  T  act,  B  subset
CD19/B4 −  −  B  cells,  follicular  dendritic  cells
CD29/Integrin  1 +  +  Leukocytes,  ﬁbroblasts,  endothelium,  epithelium
CD31/PECAM-1  −  −  Platelets,  gran,  endothelium,  dendritic  cells,  mono  subset,  T  subset,  B
subset,  lymphokine-activated  killer  cell
CD34/Mucocialin  −  −  Hematopoietic  precursors,  capillary  endothelium,  bone  marrow  stromal
cells, mast  cells
CD44 +  +  Broad,  memory  T,  ﬁbroblast,  epithelium,  endothelium,  cancer  stem  cells
CD45 −  −  Leukocytes,  not  mature  erythrocytes
CD49a/Integrin  I +  ?  T  act,  endothelium
CD51/Integrin  V +  +  Platelets,  megakaryocytes,  endothelium,  osteoblasts,  melanoma
CD56/NCAM-1  +  +  Neural  tissue,  multiple  isoforms
CD73/5′-Nucleotidase  +  +  T  subset,  B  subset,  follicular  dendritic  cells,  endothelium,  bone  marrow
stromal  cells
CD90/THY1  +  +  Thymocytes,  T  cells,  hematopoietic  subset,  neurons
CD105/Endoglin  +  +  Endothelium,  bone  marrow  cell  subset,  mac  act
CD106/VCAM-1  +  +  Endothelium  act,  follicular  dendritic  cells,  bone  marrow  myeloid
CD117/c-Kit  +  ?  Hematopoietic  stem  and  progenitors,  neural  crest-derived  melanocytes,
primordial  germ  cells,  mast  cells
CD140/PDGFR +  +  Fibroblasts,  smooth  muscle,  glial  cells,  chondrocytes
CD140/PDGFR +  +  Fibroblasts,  smooth  muscle,  glial  cells,  chondrocytes
CD146/MCAM  +  ?  Embryonic  tissue,  mammary  tumors
CD166/ALCAM  +  +  Neurons,  T  act,  mono,  epithelium,  ﬁbroblasts
CD271/LNGFR  +  ?  Neurons,  mesenchymal  stem  cells
Nestin +  +  Neural  stem  cells,  glioma  stem  cells
Stro-1 +  ?  Mesenchymal  stem  cells
Sca-1 ?  +  Bone  marrow  hematopietic  stem  cells  and  precursors,  bone  marrow
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+: positive selection, −: negative selection, ?: unknown.
steogenic  differentiation  [51,53].  Therefore,  multi-potent
CSCs  have  been  isolated  from  adults  [49]  or  produced  from
nduced  pluripotent  stem  (iPS)  cells  [54]  with  the  goal  of
pplication  to  regenerative  medicine,  e.g., in  craniofacial
one  regeneration  [55].
. Bone marrow-derived mesenchymal stem
ells  (BM-MSCs)
n  1970,  adherent  ﬁbroblastic  cells  were  isolated  from  the
one  marrow  as  colony-forming  unit  ﬁbroblasts  (CFU-F)  [56].
n  the  early  1990s,  these  cells  were  recognized  to  differen-
iate  into  various  mesenchymal  tissues  [57].  Subsequently,
he  proliferative  ability  of  human  bone  marrow-derived
ells  partially  attached  to  plastic  dishes  was  reported  [17].
hese  cells  could  directly  differentiate  into  osteoblasts,
hondrocytes,  and  adipocytes  in  vitro. However,  these
lastic-adherent  cells  are  heterogeneous  bulk  BM-MSCs
nd  contain  unique  subsets  of  BM-MSCs  [58—60].  There-
ore,  inconsistent  research  outcomes  cannot  be  completely
voided  when  using  this  traditional  culture  method,  which
as  made  it  difﬁcult  to  analyze  the  true  phenotype  and  char-
cteristics  of  BM-MSCs.Please  cite  this  article  in  press  as:  Niibe  K,  et  al.  The  po
ral  crest  cell  phenotypes  as  a  cell  source  for  regenerati
http://dx.doi.org/10.1016/j.jdsr.2016.09.001
To  date,  the  lack  of  unique  markers  has  made  it  difﬁcult
o  deﬁne  BM-MSC  origins,  physiological  roles,  relationships
ith  other  stem  cells,  and  in  vivo  localization.  In  2002,  the
ational  Institutes  of  Health  (NIH)  described  basic  research
4
H
ﬂtem  cells
n  MSCs  in  the  ‘‘Weekly  NIH  Funding  Opportunities  and
otices’’,  encouraging  researchers  to  identify  novel  mark-
rs  for  MSC  identiﬁcation  to  enhance  isolation  techniques
nd  facilitate  the  development  of  ex  vivo  stem  cell  expan-
ion  systems.  To  date,  several  MSC  cell  surface  markers
ave  been  reported  (Table  1),  although  hallmark,  univer-
ally  accepted  cell  surface  markers  for  MSC  detection  still
o  not  exist.
. Enriched MSCs from limb bone marrow
n  2009,  Morikawa  et  al.  [25]  ﬁrst  reported  the  prospec-
ive  isolation  of  enriched  mouse  BM-MSCs  (mBM-MSCs)  using
 combination  of  deﬁned  MSC  surface  markers  and  ﬂow
ytometry.  This  population  of  isolated  mBM-MSCs  was  more
omogenous  than  mBM-MSCs  isolated  using  the  traditional
lastic-adherence  technique,  and  the  enriched  mBM-MSCs
ould  be  analyzed  and  applied  freshly  without  requiring  cell
ulture  after  the  initial  ﬂow  cytometric  cell  sorting.  Similar
o  traditionally  isolated  mBM-MSCs,  the  proliferative  abil-
ty  and  differentiation  capacity  of  the  sorted  cells  can  be
valuated  by  cell  culture.tential  of  enriched  mesenchymal  stem  cells  with  neu-
ve  dentistry.  Japanese  Dental  Science  Review  (2016),
.1.  Enriched  mBM-MSCs  (PS  mBM-MSCs)
ighly  enriched  populations  of  mBM-MSCs  can  be  isolated  by
ow  cytometry  as  demonstrated  for  the  PDGFR+,  Sca-1+,
ARTICLE IN PRESS+ModelJDSR-169; No. of Pages 9
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Figure  2  Schematic  diagram  illustrating  mBM-MSC  isolation  by  ﬂow  cytometry  [27,61].  Crushed  bone  fragments  from  adult  mouse
tibia are  incubated  in  cell  culture  medium  with  collagenase  to  obtain  a  cell  suspension.  Cells  are  stained  with  monoclonal  antibodies
against CD45,  Ter119,  PDGFR,  and  Sca-1.  After  staining,  cells  are  sorted  using  a  ﬂow  cytometer  (see  details  in  the  protocol  article
[72]).  Sorted  Sca-1−/Ter119−/PDGFR+/Sca-1+ cells  (PS  mBM-MSCs:  enriched  mBM-MSCs)  differentiate  into  cells  of  mesenchymal
lineage (osteoblasts,  adipocytes,  and  chondrocytes)  and  neural  crest  lineage  (neurons,  glia,  and  smooth  muscle  cells).  Phase:  phase
contrast microscope  image;  Os:  osteoblasts  (alkaline  phosphatase);  Ad:  adipocytes  (Oil  Red  O);  Ch:  chondrocytes  (toluidine  blue);
:  GF
p
c
c
r
N
e
p
d
e
d
d
m
l
t
[
f
i
c
m
4
D
t
b
RNeu: neurons  (III  tubulin);  Gl:  glia  (glial  ﬁbrillary  acidic  protein
detected.
CD45−,  Ter119− population  [19,25]  (PS  mBM-MSCs:  Fig.  2).
PDGFR  is  an  NCC  marker  that  is  highly  expressed  par-
ticularly  in  cranial  NCCs  [38].  PS  mBM-MSCs  (so-called
‘‘puriﬁed  mouse  MSCs’’)  have  a  CFU-F  frequency  approx-
imately  120,000-fold  higher  than  that  of  unfractionated
bulk  bone  marrow  mononuclear  cells  and  show  superior
proliferative  capacity  in  adherent  cultures  [19,25].  More-
over,  PS  mBM-MSCs  maintain  their  differentiation  capacity
toward  osteoblasts,  adipocytes  and  chondrocytes  [19,25,27]
(Fig.  2).  Additionally,  PS  mBM-MSCs  can  differentiate  into
cells  of  neural  crest  lineage,  including  neurons,  glia,  and
smooth  muscle  cells  [25,27].
Furthermore,  PS  mBM-MSCs  innately  express  Klf4  and
c-Myc  at  levels  similar  to  those  in  embryonic  stem  (ES)
cells  [61].  Consequently,  PS  mBM-MSCs  have  been  demon-
strated  to  efﬁciently  produce  iPS  cells  with  introduction
of  three  deﬁned  factors,  i.e., Oct3,  Klf4,  and  Sox2,
without  requiring  c-Myc  (3F-PS-mBM-MSCs).  Moreover,  3F-
PS-mBM-MSC-derived  iPS  cells  can  efﬁciently  produce
germline-competent  chimeric  mice  [61].  These  ﬁndings
suggest  that  PS  mBM-MSCs  can  be  maintained  in  an  undif-
ferentiated  stem  cell  state  while  retaining  multi-potency.
These  characteristics  may  facilitate  analysis  of  the  intrinsic
characteristics  and  role  of  MSCs  in  bone  marrow.
4.2.  Origins  of  PS  mBM-MSCs:  mesoderm  and
neural crestPlease  cite  this  article  in  press  as:  Niibe  K,  et  al.  The  po
ral  crest  cell  phenotypes  as  a  cell  source  for  regenerati
http://dx.doi.org/10.1016/j.jdsr.2016.09.001
The  origins  of  BM-MSCs  have  been  investigated  using  deﬁned
markers  and  transgenic  mice.  During  development,  the  ver-
tebrate  limb  bone  marrow  is  developed  from  the  lateral
l
a
M
tAP);  SM:  smooth  muscle  cells  (-smooth  muscle  actin);  ND:  not
late  mesoderm  [62—64].  Therefore,  BM-MSCs  have  been
onsidered  to  be  derived  from  the  mesoderm  [62—64].  In
ontrast,  Takashima  et  al.  [28]  have  shown  that  Sox1+ neu-
oepithelium  could  give  rise  to  mBM-MSCs,  suggesting  that
CCs  supply  the  progenitors  of  BM-MSCs  during  embryogen-
sis  and  later  are  replaced  by  MSCs  from  other  origins  in
ostnatal  development.
PS  mBM-MSCs  contain  both  mesoderm-  and  neural  crest-
erived  cells.  A  previous  study  using  adult  transgenic  mice
xpressing  Mesp1  (a  mesodermal  cell  lineage  marker  in  early
evelopment  [65])  showed  that  PS  mBM-MSCs  are  partly
erived  from  the  mesoderm  [27].  Interestingly,  Mesp1+ PS
BM-MSCs  can  differentiate  into  not  only  mesenchymal-
ineage  cells  but  also  neural  crest-lineage  cells,  even  though
hey  are  derived  from  the  mesoderm  [27]. Morikawa  et  al.
25]  also  revealed  that  PS  mBM-MSCs  originate  partially
rom  the  neural  crest  using  adult  transgenic  mice  express-
ng  neural  crest-speciﬁc  P0-Cre/Floxed-EGFP.  These  neural
rest-derived  PS  mBM-MSCs  can  also  differentiate  into
esenchymal-  and  neural  crest-lineage  cells  [25].
.3.  Enriched  human  BM-MSCs  (LTV  hBM-MSCs)
espite  the  widespread  clinical  use  of  hBM-MSCs,  uncer-
ainty  exists  with  respect  to  many  aspects  of  their  biology
ecause  of  the  lack  of  unique  markers,  similar  to  mBM-MSCs.
ecently,  Mabuchi  et  al.  [26]  succeeded  in  prospectively  iso-tential  of  enriched  mesenchymal  stem  cells  with  neu-
ve  dentistry.  Japanese  Dental  Science  Review  (2016),
ating  enriched  hBM-MSCs  by  combining  the  LNGFR+,  THY1+,
nd  VCAM-1+ markers  (LTV  hBM-MSCs).  Collectively,  LTV  hBM-
SCs  demonstrate  a  CFU-F  frequency  ∼200,000  times  higher
han  that  observed  for  unfractionated  bone  marrow  cells.
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Figure  3  Schematic  diagram  illustrating  the  prospects  of  using  enriched  hBM-MSCs  from  bone  marrow  for  craniofacial  tissue/organ
regeneration.  Craniofacial  mesenchyme  develops  from  migrating  cranial  NCCs.  A  certain  portion  of  trunk  NCCs  migrates  to  limb
bone marrow,  where  these  cells  reside  as  a  part  of  adult  BM-MSCs.  Therefore,  enriched  hBM-MSCs,  which  are  isolated  from  the
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dM-MSC population  using  a  ﬂow  cytometer  (LNGFR+,  THY1+,  an
re expected  to  be  a  useful  cell  source  for  craniofacial  regener
sing  a  ﬂow  cytometric  single-cell  clonal  assay,  clonal  LTV
BM-MSCs  have  been  observed  to  differentiate  into  cells  of
esenchymal  lineage.  In  addition,  LTV  hBM-MSCs  can  differ-
ntiate  into  cells  of  neural  crest  lineage  including  neuronal
nd  smooth  muscle  cells  (Mabuchi  et  al.  unpublished  data).
This  result  implies  that  LTV  hBM-MSCs  contain  neural
rest-derived  MSCs.  More  recently,  enriched  MSCs  have  also
een  isolated  from  MSCs  in  the  human  dental  pulp  using  cell-
urface  markers  LNGFR  and  THY1  [66].  Because  craniofacial
issues  originate  from  cranial  NCCs,  human  LTV  hBM-MSCs
re  expected  to  be  an  important  cell  source  for  achieving
ffective  stem  cell-based  regenerative  therapy  of  craniofa-
ial  tissues.
. Potential of enriched BM-MSCs as a cell
ource  for oral tissue/organ regeneration
ew  treatment  methods  are  essential  to  repair  large  defects
n  periodontal  tissues  [1].  Stem  cell  transplantation  strate-
ies  using  the  whole  population  of  BM-MSCs  have  been
uccessfully  used  in  dentistry  to  regenerate  these  tissues,
lthough  further  research  is  required  to  establish  more
eliable  protocols  [11].  It  has  been  suggested  that  a  cell
ource-dependent  phenotype  similar  to  that  of  the  recip-
ent  site  is  associated  with  enhanced  capacity  of  bone
egeneration  upon  transplantation  [67].  Embryologically,
ental  mesenchymal  tissues  are  generated  by  cranial  NCCs.Please  cite  this  article  in  press  as:  Niibe  K,  et  al.  The  po
ral  crest  cell  phenotypes  as  a  cell  source  for  regenerati
http://dx.doi.org/10.1016/j.jdsr.2016.09.001
ecause  enriched  BM-MSCs  also  partly  originate  from  NCCs,
t  would  be  expected  that  puriﬁed  BM-MSCs  with  the  NCC
henotype  have  an  advantage  in  effective  regeneration  of
raniofacial  tissues/organs.
w
s
t
iM-1+ cells:  LTV  hBM-MSCs),  show  an  NCC  phenotype,  and  they
 medicine.
Tooth  development  requires  an  epithelial-mesenchymal
nteraction.  Mouse  dental  epithelium  in  its  embryonic  early
evelopmental  stage  stimulates  mouse  non-dental  mes-
nchyme  to  differentiate  into  dental  mesenchyme  [68].
or  tooth  bioengineering,  single-cell  populations  of  fetal
ental  epithelium  and  mesenchyme  can  be  used  for  gen-
rating  bioengineered  tooth  germ,  which  can  develop
nto  fully  functional  teeth  at  transplanted  sites  in  mouse
andibular  bone  [7,9].  Advanced  technology  based  on
hree-dimensional  organ-germ  culture  using  fetal  dental
ells  enables  the  fabrication  of  a  bioengineered  tooth  unit
hat  regenerates  not  only  the  tooth  but  also  the  peri-
dontal  tissues  [10].  These  ﬁndings  indicate  that  cells
rom  embryonic  oral  epithelium  and  neural-crest-derived
esenchyme  can  be  used  to  construct  tooth  and  periodon-
al  tissues.  Although  these  technologies  have  opened  the
oor  to  address  unmet  clinical  needs  in  tooth  regeneration
herapy,  the  limited  nature  of  cell  sources  for  tooth  bioengi-
eering  make  them  difﬁcult  apply  clinically.
Recently,  Jiang  et  al.  [69]  showed  that  postnatal  den-
al  epithelium  and  mesenchyme  stem/progenitor  cells  in
at  incisors  can  form  tooth-like  structures.  Other  research
as  shown  that  mouse  embryonic  dental  mesenchyme  cells,
hen  reconstituted  with  adult  human  gingival  epithelial
ells  [70]  or  cell  sheets  derived  from  iPS  cells  [8],  form
ooth-like  structures.  Additionally,  adult  mBM-MSCs  were
reviously  shown  to  successfully  replace  dental  mesenchy-
al  cells  in  forming  a  tooth  primordium  [71]. Because  the
ental  mesenchyme  originates  in  NCCs,  enriched  BM-MSCs,tential  of  enriched  mesenchymal  stem  cells  with  neu-
ve  dentistry.  Japanese  Dental  Science  Review  (2016),
hich  possess  neural  crest  phenotypes,  would  have  more
imilar  characteristics  to  dental  mesenchyme  compared  to
he  general  BM-MSC  population.  If  the  differentiation  capac-
ty  of  enriched  BM-MSCs  is  comparable  to  that  of  dental
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mesenchyme,  they  could  be  a  promising  source  for  dental
mesenchyme  regeneration.
6. Future challenges for enriched BM-MSCs
Basic  research  into  enriched  BM-MSCs  is  in  its  infancy.  These
cells  have  been  shown  to  possess  some  authentic  BM-MSC
characteristics;  however,  a  complete  BM-MSC  marker  set  is
yet  to  be  deﬁned.  In  addition,  hBM-MSC  markers  are  differ-
ent  from  mBM-MSC  markers.  Therefore,  simple  comparisons
of  BM-MSCs  across  species  are  difﬁcult.  The  identiﬁcation
of  universal  BM-MSC  markers  should  greatly  enhance  the
progress  of  basic  research  into  BM-MSCs.  Although  attempts
to  regenerate  tooth  and  periodontal  tissues  using  enriched
BM-MSCs  have  been  initiated,  one  of  the  critical  issues  for
clinical  application  of  enriched  BM-MSCs  is  their  limited
expansion  potential  in  traditional  adherent  culture  systems.
Therefore,  it  is  important  to  elucidate  the  mechanisms  that
regulate  proliferation  and  differentiation  of  enriched  BM-
MSCs  to  develop  suitable  cell  culture  systems.
7. Concluding remarks
In  this  review,  we  have  outlined  two  unique  aspects  of
enriched  BM-MSCs  (PS  mBM-MSCs  and  LTV  hBM-MSCs):  (1)
They  partially  contain  NCSCs  derived  from  the  neural  crest,
and  (2)  their  differentiation  potential  is  similar  to  that  of
NCCs  because  they  can  also  differentiate  into  neural  crest
lineage  cells.  The  majority  of  the  craniofacial  mesenchyme
is  developed  from  the  neural  crest.  Therefore,  these  unique
characteristics  of  multi-potent  enriched  BM-MSCs  with  NCC
phenotypes  imply  that  they  would  be  a  suitable  cell  source
for  craniofacial  mesenchymal  tissue/organ  regeneration,
not  only  to  form  bioengineered  tooth  organs,  but  also  for
craniofacial  bone  regeneration  or  periodontal  tissue  regen-
eration  (Fig.  3).  Further  biological  research  on  enriched
BM-MSCs  is  required  to  achieve  efﬁcient  cell-based  regen-
erative  dentistry.
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